LGALS3 and metabolic dysfunction-associated steatohepatitis: GR-MD-02 (belapectin), an inhibitor of galectin-3 that reduces liver fibrosis, was evaluated for its safety and efficacy in patients with MASH, liver cirrhosis, and PH [342].